Elevated levels of plasma fibrinogen, the major structural protein of blood clots, are strongly associated with cardiovascular disease. But while fibrinogen fulfills many etiological criteria, it remains unclear whether elevated levels of fibrinogen are an important cause of cardiovascular disease or an effect of it. This link between fibrinogen and cardiovascular disease may lie not only in the level of plasma fibrinogen, but also in its composition. We found that elevated levels of a minor fibrinogen isoform called gamma prime (gammaA/gamma') fibrinogen were associated with coronary artery disease. This observation is consistent with findings from an independent research group, who reported an association between the ratio of gammaA/gamma' fibrinogen to total fibrinogen and arterial thrombosis. To date, however, no study has directly tested the association between gammaA/gamma' fibrinogen and traditional cardiovascular disease risk factors (e.g. smoking, hypertension, diabetes, and cholesterol). Furthermore, the clinical and biochemical properties of gammaA/gamma' fibrinogen implicate it in direct mediation of cardiovascular disease pathogenesis. In this application, we propose three Specific Aims: 1) To determine the distribution of gammaA/gammaA fibrinogen and gammaAgamma' fibrinogen among the Framingham Offspring cohort and investigate gender- and age-specific characteristics. 2) To determine the relationship between fibrinogen isoforms and established cardiovascular disease risk factors. 3) To determine if the fibrinogen isoforms in plasma are independently associated with CVD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HL075006-02
Application #
7012824
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Link, Rebecca P
Project Start
2005-02-01
Project End
2007-11-30
Budget Start
2005-12-01
Budget End
2007-11-30
Support Year
2
Fiscal Year
2006
Total Cost
$147,452
Indirect Cost
Name
Oregon Health and Science University
Department
Pathology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lovely, Rehana S; Yang, Qiong; Massaro, Joseph M et al. (2011) Assessment of genetic determinants of the association of ?' fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol 31:2345-52
Lovely, Rehana S; Kazmierczak, Steven C; Massaro, Joseph M et al. (2010) Gamma' fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem 56:781-8
Rein, Chantelle M; Anderson, Brian L; Ballard, Morgan M et al. (2010) Severe bleeding in a woman heterozygous for the fibrinogen gammaR275C mutation. Blood Coagul Fibrinolysis 21:494-7
Flood, Veronica H; Al-Mondhiry, Hamid A; Rein, Chantelle M et al. (2008) Fibrinogen Hershey IV: a novel dysfibrinogen with a gammaV411I mutation in the integrin alpha(IIb)beta(3) binding site. Thromb Haemost 99:1008-12
Lovely, Rehana S; Rein, Chantelle M; White, Tara C et al. (2008) gammaA/gamma'fibrinogen inhibits thrombin-induced platelet aggregation. Thromb Haemost 100:837-46
Lovely, Rehana S; Boshkov, Lynn K; Marzec, Ulla M et al. (2007) Fibrinogen gamma'chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol 139:494-503
Mannila, M N; Lovely, R S; Kazmierczak, S C et al. (2007) Elevated plasma fibrinogen gamma'concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 5:766-73
Sabo, T Michael; Farrell, David H; Maurer, Muriel C (2006) Conformational analysis of gamma' peptide (410-427) interactions with thrombin anion binding exosite II. Biochemistry 45:7434-45
Flood, Veronica H; Al-Mondhiry, Hamid A; Farrell, David H (2006) The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance. Br J Haematol 134:220-6